Occupational medicine guideline says cannabis is not recommended for common workplace injuries and conditions

An ACOEM guideline found no quality evidence supporting cannabis for common work-related pain conditions, documented many adverse effects, and recommended against use in safety-sensitive positions.

Feinberg, Steven D et al.·Journal of occupational and environmental medicine·2025·Strong EvidenceReview
RTHC-06444ReviewStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Some evidence for MS spasticity, but no quality evidence for back pain, radiculopathy, neuropathic pain, or other common work-related pain. Quality evidence supports lack of efficacy for postoperative pain. Documented adverse effects include cancers, cardiovascular diseases, psychotic disorders, and safety risks.

Key Numbers

Efficacy evidence: some for MS spasticity only. No quality evidence for: back pain, radiculopathy, neuropathic pain. Evidence against: postoperative pain. Harms: cancers, cardiovascular, psychotic disorders, safety risks.

How They Did This

Evidence-based guideline developed using ACOEM methodology, systematically reviewing evidence on cannabis efficacy and safety for work-related conditions.

Why This Research Matters

As legalization expands, employers face pressure to allow cannabis. This provides evidence-based grounds for workplace policies, particularly for safety-sensitive positions.

The Bigger Picture

The gap between public perception of cannabis as a pain treatment and the evidence base has direct workplace safety implications.

What This Study Doesn't Tell Us

Guidelines reflect evidence at publication; new trials may change recommendations. May reflect conservative occupational medicine perspective.

Questions This Raises

  • ?Will ongoing trials change the chronic pain picture?
  • ?How should employers handle workers using cannabis for other conditions?

Trust & Context

Key Stat:
No quality evidence of efficacy for back pain, neuropathic pain, or other common work conditions
Evidence Grade:
Systematic evidence-based guideline using ACOEM methodology, a high standard for occupational medicine recommendations.
Study Age:
Published in 2025.
Original Title:
Cannabis.
Published In:
Journal of occupational and environmental medicine, 67(12), e860-e871 (2025)
Database ID:
RTHC-06444

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Does cannabis work for workplace injury pain?

According to this guideline, no quality evidence supports cannabis for common work-related conditions. Only MS spasticity has some supporting evidence.

Can workers use cannabis in safety-sensitive jobs?

The guideline recommends against it, citing documented adverse effects on cognition, reaction time, and safety.

Read More on RethinkTHC

Cite This Study

RTHC-06444·https://rethinkthc.com/research/RTHC-06444

APA

Feinberg, Steven D; Aronoff, Gerald M; Ausfahl, James; Bruns, Daniel; Darnall, Beth D; Goldberg, Robert L; Haldeman, Scott; Lessenger, James E; Mandel, Steven; Mayer, Tom G; Navani, Annu H; Osbahr, Albert J; Warren, Pamela A; Winters, Thomas H; Harris, Jeffrey S; Hegmann, Kurt T. (2025). Cannabis.. Journal of occupational and environmental medicine, 67(12), e860-e871. https://doi.org/10.1097/JOM.0000000000003548

MLA

Feinberg, Steven D, et al. "Cannabis.." Journal of occupational and environmental medicine, 2025. https://doi.org/10.1097/JOM.0000000000003548

RethinkTHC

RethinkTHC Research Database. "Cannabis." RTHC-06444. Retrieved from https://rethinkthc.com/research/feinberg-2025-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.